Business Context and Reporting Period
This Form 8-K is a current report filed by American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc. in metadata) on May 8, 2019, regarding events occurring on May 3, 2019. The filing details a corporate action involving a stock reverse split and amendments to the company's Articles of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Stock Reverse Split: The Board of Directors approved a 1-for-18 reverse split of the Company's authorized and issued common stock.
- Effective Date: The Financial Industry Regulatory Authority (FINRA) confirmed the reverse split would take effect on May 8, 2019.
- Amendment Filing: A certificate of amendment to the Articles of Incorporation was filed with the Nevada Secretary of State on May 3, 2019.
- Shareholder Approval: The Board authorized the reverse split without shareholder approval pursuant to Section 78.207 of the Nevada Revised Statutes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the execution of the reverse split.
Investor Verification Checklist
- Verify the post-split share count and adjusted share price on May 8, 2019.
- Confirm the updated authorized common stock limits in the amended Articles of Incorporation.
- Review the rationale for the 1-for-18 split ratio to ensure alignment with market capitalization goals.
- Check for any subsequent filings regarding the impact of the split on outstanding options or warrants.